{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:28:46Z","timestamp":1785018526381,"version":"3.55.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Hellenic Group for the Study of IBD","award":["2020EOMIFNEp5"],"award-info":[{"award-number":["2020EOMIFNEp5"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) is a chronic inflammatory disease that impairs health-related quality of life (HRQoL). We evaluated the effect of approved therapies on HRQoL in adults with moderate-to-severe UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched Medline, Embase, CENTRAL, and gray literature through December 2024 for randomized controlled trials (RCTs) of approved therapies. The primary outcome was change in Inflammatory Bowel Disease Questionnaire (IBDQ) score during induction and maintenance. Secondary outcomes included changes in Short Form-36 (SF-36) Mental and Physical Component Scores, Work Productivity and Activity Impairment in UC (WPAI-UC), and rates of IBDQ response (\u226516-point increase) and remission (score \u2265170). Minimal clinically important differences were prespecified. Subgroup analyses based on prior biologic exposure were performed for primary outcome. Frequentist random-effects network meta-analyses were conducted, and confidence in estimates was assessed using the CINeMA (Confidence In Network Meta-Analysis) framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight RCTs were included; 26 reported HRQoL outcomes during induction and 15 during maintenance. During induction, clinically meaningful improvements in IBDQ were observed with upadacitinib, filgotinib, and guselkumab. During maintenance, upadacitinib 30\u2009mg and vedolizumab showed HRQoL benefits, although clinical meaningfulness was not consistently demonstrated. SF-36 improvements were modest overall, with upadacitinib and vedolizumab showing selective advantages, while WPAI-UC benefits were observed with upadacitinib, vedolizumab, and ustekinumab. Upadacitinib consistently ranked highest in IBDQ response and remission, while other therapies showed variable efficacy across outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Advanced therapies vary in their impact on HRQoL, with some demonstrating clinically meaningful improvements in UC. These findings support integrating HRQoL into treatment selection and shared decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf210","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:02:00Z","timestamp":1763816520000},"source":"Crossref","is-referenced-by-count":2,"title":["Systematic review and network meta-analysis: evaluating the impact of advanced therapies for moderate-to-severe ulcerative colitis on health-related quality of life"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3637-9011","authenticated-orcid":false,"given":"Anastasia","family":"Katsoula","sequence":"first","affiliation":[{"name":"Gastroenterology Division-Second Propaedeutic Department of Internal Medicine\u2014Medical School, Aristotle University of Thessaloniki, Hippokration Hospital , Thessaloniki,","place":["Greece"]},{"name":"Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki , Thessaloniki,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1497-4992","authenticated-orcid":false,"given":"Paschalis","family":"Paschos","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki , Thessaloniki,","place":["Greece"]},{"name":"First Department of Internal Medicine, \u201cPapageorgiou\u201d Hospital , Thessaloniki,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5134-2401","authenticated-orcid":false,"given":"Konstantinos","family":"Malandris","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki , Thessaloniki,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Styliani","family":"Kalogirou","sequence":"additional","affiliation":[{"name":"Gastroenterology Division-Second Propaedeutic Department of Internal Medicine\u2014Medical School, Aristotle University of Thessaloniki, Hippokration Hospital , Thessaloniki,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Bettina","family":"Haidich","sequence":"additional","affiliation":[{"name":"Department of Hygiene and Epidemiology, Medical School, Aristotle University of Thessaloniki , Thessaloniki,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Giouleme","sequence":"additional","affiliation":[{"name":"Gastroenterology Division-Second Propaedeutic Department of Internal Medicine\u2014Medical School, Aristotle University of Thessaloniki, Hippokration Hospital , Thessaloniki,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-4072","authenticated-orcid":false,"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki , Thessaloniki,","place":["Greece"]},{"name":"Harris Manchester College, University of Oxford , Oxford,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2025121903313292200_jjaf210-B1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"2025121903313292200_jjaf210-B2","doi-asserted-by":"publisher","first-page":"c186","DOI":"10.1136\/bmj.c186","article-title":"The routine use of patient reported outcome measures in healthcare settings","volume":"340","author":"Dawson","year":"2010","journal-title":"BMJ"},{"key":"2025121903313292200_jjaf210-B3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2025121903313292200_jjaf210-B4","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1093\/ibd\/izae083","article-title":"Challenges in IBD research 2024: pragmatic clinical research","volume":"30","author":"Allegretti","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025121903313292200_jjaf210-B5","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/apt.15005","article-title":"Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life","volume":"48","author":"Paschos","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121903313292200_jjaf210-B6","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ibd\/izae163","article-title":"Comparative efficacy of biologics and small molecule therapies in improving patient-reported outcomes in ulcerative colitis: systematic review and network meta-analysis","volume":"31","author":"Shehab","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025121903313292200_jjaf210-B7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2025121903313292200_jjaf210-B8","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","author":"Li","year":"2024"},{"key":"2025121903313292200_jjaf210-B9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12874-018-0483-0","article-title":"Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review","volume":"18","author":"Weir","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2025121903313292200_jjaf210-B10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn\u2019s Relapse Prevention Trial Study Group","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"key":"2025121903313292200_jjaf210-B11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2025121903313292200_jjaf210-B12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2025121903313292200_jjaf210-B13","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/j.1365-2036.2009.03966.x","article-title":"Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn\u2019s disease","volume":"29","author":"Coteur","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121903313292200_jjaf210-B14","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.14309\/00000434-200709002-00962","article-title":"Minimally important difference for WPAI: CD scores: defining relevant impact on work productivity in active Crohn\u2019s disease","volume":"102","author":"Sandborn","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"2025121903313292200_jjaf210-B15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025121903313292200_jjaf210-B16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2025121903313292200_jjaf210-B17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"key":"2025121903313292200_jjaf210-B18","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health."},{"key":"2025121903313292200_jjaf210-B19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"2025121903313292200_jjaf210-B20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int J Epidemiol"},{"key":"2025121903313292200_jjaf210-B21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jclinepi.2014.08.012","article-title":"Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data","volume":"68","author":"Rhodes","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"2025121903313292200_jjaf210-B22","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"2025121903313292200_jjaf210-B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"2025121903313292200_jjaf210-B24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"2025121903313292200_jjaf210-B25","year":"2020"},{"key":"2025121903313292200_jjaf210-B26","year":"2022"},{"key":"2025121903313292200_jjaf210-B27","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2025121903313292200_jjaf210-B28","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"2025121903313292200_jjaf210-B29","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"key":"2025121903313292200_jjaf210-B30","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2025121903313292200_jjaf210-B31","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1572-0241.2007.01094.x","article-title":"The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients","volume":"102","author":"Feagan","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"2025121903313292200_jjaf210-B32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"2025121903313292200_jjaf210-B33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"2025121903313292200_jjaf210-B34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/ecco-jcc\/jjz031","article-title":"Rapid changes in laboratory parameters and early response to adalimumab: a pooled analysis from patients with ulcerative colitis in two clinical trials","volume":"13","author":"Hanauer","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025121903313292200_jjaf210-B35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2014","journal-title":"J Gastroenterol"},{"key":"2025121903313292200_jjaf210-B36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"2025121903313292200_jjaf210-B37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"2025121903313292200_jjaf210-B38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2025121903313292200_jjaf210-B39","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121903313292200_jjaf210-B40","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"2025121903313292200_jjaf210-B41","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2025121903313292200_jjaf210-B42","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"2025121903313292200_jjaf210-B43","doi-asserted-by":"publisher","first-page":"S807","DOI":"10.14309\/01.ajg.0000953880.47700.a5","article-title":"Guselkumab improves health-related quality of life in patients with moderately to severely active ulcerative colitis: results from the QUASAR phase 3 induction study","volume":"118","author":"Bressler","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025121903313292200_jjaf210-B44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"2025121903313292200_jjaf210-B45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121903313292200_jjaf210-B46","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"2025121903313292200_jjaf210-B47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2025121903313292200_jjaf210-B48","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/s0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet (London, England)"},{"key":"2025121903313292200_jjaf210-B49","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2025121903313292200_jjaf210-B50","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/s0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet (London, England)"},{"key":"2025121903313292200_jjaf210-B51","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/ibd\/izac260","article-title":"Induction and maintenance treatment with upadacitinib improves health-related quality of life in patients with moderately to severely active ulcerative colitis: phase 3 study results","volume":"29","author":"Pan\u00e9s","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2025121903313292200_jjaf210-B52","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/s2468-1253(23)00208-x","article-title":"Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121903313292200_jjaf210-B53","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"2025121903313292200_jjaf210-B54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12876-015-0239-9","article-title":"Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes","volume":"15","author":"Pan\u00e9s","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"2025121903313292200_jjaf210-B55","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2025121903313292200_jjaf210-B56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies","volume":"12","author":"Pan\u00e9s","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2025121903313292200_jjaf210-B57","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/s0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet (London, England)"},{"key":"2025121903313292200_jjaf210-B58","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/ecco-jcc\/jjad018","article-title":"Filgotinib improved health-related quality of life and led to comprehensive disease control in individuals with ulcerative colitis: data from the SELECTION trial","volume":"17","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025121903313292200_jjaf210-B59","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121903313292200_jjaf210-B60","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121903313292200_jjaf210-B61","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Journal of Crohn\u2019s and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf210\/65492462\/jjaf210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/11\/jjaf210\/65492462\/jjaf210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/11\/jjaf210\/65492462\/jjaf210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:31:56Z","timestamp":1766133116000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf210\/8341555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf210","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11]]},"article-number":"jjaf210"}}